Biocompatibles still talking with J&J
Thursday 24 July 1997
Shares in Biocompatibles have slumped by more than 400p over the last few weeks to 997p on concerns that a delay in concluding the deal meant the tie-up could fall through. An initial agreement to market its coating to J&J expired last month.
Julian Steadman, Biocompatibles' finance director, said yesterday that the talks were definitely ongoing. However, J&J's request to extend the negotiations to include Biocompatible's recently acquired range of modern stents, used to keep blood vessels open, as well as its coating had protracted the talks. "A deal is several weeks away. But J&J is such a big player in the US, it is important to conclude this properly." J&J controls 80 per cent of the fast growing US stent market. Erling Refsum, analyst at Yamaichi said: "It is clear that Biocompatibles is not in any difficulties over these negotiations. It is an even better sign that J&J has asked for the stents to be included in the negotiations."
J&J had wanted to market Biocompatibles unique coating, which resists infection and blood clots and can be used to deliver drugs, to boost sales of its own stent range. However, J&J has relatively old products and with competition increasing in the US, it has been losing market share.
As a result J&J is keen to acquire rights to Biocompatibles' new stent range. "It is clear that J&J needs Biocompatibles more than the other way round," said one analyst. Observers speculate that Biocompatibles can demand a princely royalty rate of at least 25 per cent on any products licensed to J&J.
Threat of 'catastrophic cascade of collisions' must be averted, warn scientists
Wellcome Image Awards: The most striking images from the world of science, including breast cancer cells under chemical attack and a photographer’s own kidney stone
Space debris orbiting Earth to be destroyed with giant lasers fired from Australia
Swarm of killer bees sting woman 1,000 times
Oscar Pistorius murder trial: Athlete repeatedly sick as court hears 'graphic details' of Reeva Steenkamp's post-mortem
How climate change helped Genghis Khan: Scientists believe a sudden period of warmer weather allowed the Mongols to invade with such success
Britain's top vet sparks controversy with call for ban on slashing animals' throats in 'ritual' slaughters for halal and kosher meat products
Poor 'live like animals' says Boris's privately educated sister after going on 'poverty safari'
Exclusive: Impact of immigrants on British workers ‘negligible’
Vince Cable: Teachers 'know absolutely nothing' about the world of work
Ukraine crisis: Russia pledges to 'retaliate against sanctions' as Ukrainian president says Crimea vote will not be recognised
The quiet diplomat: Catherine Ashton - recognised and admired in all the world’s troubled countries, yet ridiculed at home
- 1 Australian man Rod Sommerville reacts to bite from deadly snake by reaching for cold beer
- 2 Pakistan vs Paul Smith: Sandal-wearers bemused by famed British designer's attempts to sell traditional Peshawari chappal-style shoes for the distinctly untraditional sum of £300
- 3 North Korea elections: Kim Jong-un wins 100% of the vote
- 4 Steve Irwin’s final words: Cameraman present at death opens up about deadly stingray attack for the first time
- 5 Sharknado 2: Former WWE wrestler Kurt Angle to fight second wave of flying sharks
iJobs Money & Business
£32000 - £36000 per annum + generous benefits: Pro-Recruitment Group: * TAX * ...
£55000 - £70000 per annum + benefits: Pro-Recruitment Group: In-House Corporat...
£80000 - £100000 per annum + benefits: Pro-Recruitment Group: In-House Opportu...
£30000 - £35000 per annum + generous benefits: Pro-Recruitment Group: Mixed Ta...